...
首页> 外文期刊>Therapeutic advances in musculoskeletal disease. >Dual-energy computed-tomography-based discrimination between basic calcium phosphate and calcium pyrophosphate crystal deposition in vivo
【24h】

Dual-energy computed-tomography-based discrimination between basic calcium phosphate and calcium pyrophosphate crystal deposition in vivo

机译:基于双能量计算的断层摄影基于磷酸钙基础磷酸钙和焦磷酸钙结晶沉积在体内

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background: Dual-energy computed tomography (DECT) is being considered as a non-invasive diagnostic and characterization tool in calcium crystal-associated arthropathies. Our objective was to assess the potential of DECT in distinguishing between basic calcium phosphate (BCP) and calcium pyrophosphate (CPP) crystal deposition in and around joints in vivo. Methods: A total of 13 patients with calcific periarthritis and 11 patients with crystal-proven CPPD were recruited prospectively to undergo DECT scans. Samples harvested from BCP and CPP calcification types were analyzed using Raman spectroscopy and validated against synthetic crystals. Regions of interest were placed in BCP and CPP calcifications, and the following DECT attenuation parameters were obtained: CT numbers (HU) at 80 and 140?kV, dual-energy index (DEI), electron density (Rho), and effective atomic number ( Z eff ). These DECT attenuation parameters were compared and validated against crystal calibration phantoms at two known equal concentrations. Receiver operating characteristic (ROC) curves were plotted to determine the highest accuracy thresholds for DEI and Z eff . Results: Raman spectroscopy enabled chemical fingerprinting of BCP and CPP crystals both in vitro and in vivo. DECT was able to distinguish between HA and CPP in crystal calibration phantoms at two known equal concentrations, most notably by DEI (200?mg/cm 3 : 0.037?±?0 versus 0.034?±?0, p?=?0.008) and Z eff (200?mg /cm 3 : 9.4?±?0 versus 9.3?±?0, p?=?0.01) analysis. Likewise, BCP calcifications had significantly higher DEI (0.041?±?0.005 versus 0.034?±?0.005, p?=?0.008) and Z eff (9.5?±?0.2 versus 9.3?±?0.2, p?=?0.03) than CPP crystal deposits with comparable CT numbers in patients. With an area under the ROC curve of 0.83 [best threshold value?=?0.0 39, sensitivity?=?90. 9% (81.8, 97. 7%), specificity?=?64.6% (50.0, 64. 6%)], DEI was the best parameter in distinguishing between BCP and CPP crystal depositions. Conclusion: DECT can help distinguish between crystal-proven BCP and CPP calcification types in vivo and, thus, aid in the diagnosis of challenging clinical cases, and in the characterization of CPP and BCP crystal deposition occurring in osteoarthritis.
机译:背景:双能计算机断层扫描(DECT)被认为是钙晶体相关的关节部的非侵入性诊断和表征工具。我们的目标是评估区分中的基本磷酸钙(BCP)和焦磷酸钙(CPP)晶晶体沉积在体内的基本磷酸钙(BCP)和周围的潜力。方法:招募了13例钙冠炎患者和11名患有Crystal-Proven CPPD患者,并令人医招募扫描DECT扫描。使用拉曼光谱分析从BCP和CPP钙化类型收获的样品并验证合成晶体。将感兴趣的区域置于BCP和CPP钙化中,获得以下DECT衰减参数:CT数(HU)在80和140 kV,双能指数(DEI),电子密度(RHO)和有效原子序数(z eff)。将这些DECT衰减参数进行比较和验证以两种已知的相同浓度验证晶体校准杂色。接收器操作特征(ROC)曲线被绘制以确定DEI和Z EFF的最高精度阈值。结果:拉曼光谱通过体外和体内的BCP和CPP晶体的化学指纹印刷能够。 DECT能够以两种已知的相同浓度在晶体校准杂色中区分HA和CPP,最值以由DEI(200×Mg / cm 3:0.037≤0.034≤0,p?= 0.008)和Z EFF(200?mg / cm 3:9.4?±0与9.3?±0,p?=?0.01)分析。同样,BCP钙化显着高得多(0.041?±±0.005与0.034?±0.005,p?= 0.008)和Z eff(9.5?±0.2与9.3?±0.2,p?=?0.03) CPP晶体沉积在患者中具有可比的CT号。在ROC曲线下的区域为0.83 [最佳阈值?=?0.0 39,灵敏度?=?90。 9%(81.8,97.7%),特异性?= 64.6%(50.0,64.6%)],DEI是区分BCP和CPP晶体沉积的最佳参数。结论:DECT可以帮助区分体内晶体证明的BCP和CPP钙化类型,从而有助于诊断挑战性临床病例,并在骨关节炎中表征CPP和BCP晶体沉积。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号